The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
Clinical Immunology, ISSN: 1521-6616, Vol: 215, Page: 108450
2020
- 238Citations
- 288Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations238
- Citation Indexes237
- 237
- CrossRef30
- Patent Family Citations1
- Patent Families1
- Captures288
- Readers288
- 288
Article Description
Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immune pathways. While a “cytokine storm” involving IL-6 and other cytokines has been documented, complement C3 activation has been implicated as an initial effector mechanism that exacerbates lung injury in preclinical models of SARS-CoV infection. C3-targeted intervention may provide broader therapeutic control of complement-mediated inflammatory damage in COVID-19 patients. Herein, we report the clinical course of a patient with severe ARDS due to COVID-19 pneumonia who was safely and successfully treated with the compstatin-based complement C3 inhibitor AMY-101.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1521661620303314; http://dx.doi.org/10.1016/j.clim.2020.108450; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85084215330&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/32360516; https://linkinghub.elsevier.com/retrieve/pii/S1521661620303314; https://dx.doi.org/10.1016/j.clim.2020.108450
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know